Calenda Emile, Genevois Olivier, Cardon Annie, Muraine Marc
Department of Anesthesia, Rouen University Hospital, 1 rue de Germont, Rouen cedex 76031, France.
Department of Ophthalmology, Rouen University Hospital, 1 rue de Germont, Rouen cedex 76031, France.
Int J Ophthalmol. 2014 Feb 18;7(1):110-3. doi: 10.3980/j.issn.2222-3959.2014.01.20. eCollection 2014.
To check the safety of continuation of oral anticoagulants in ophthalmic procedures requiring a peribulbar anesthesia.
A prospective case control study included 750 patients with oral anticoagulants in group A and 750 patients who had never been treated with oral anticoagulant in group B. Hemorrhages were graded as follows: 1) spot ecchymosis of eyelid and or subconjunctival hemorrhage; 2) eyelid ecchymosis involving half of the lid surface area; 3) eyelid ecchymosis all around the eye, no increase in intraocular pressure; 4) retrobulbar hemorrhage with increased intraocular pressure.
In group A, grade 1 was observed in 13 patients (1.74%) and grade 2 in 2 patients (0.26%). In group B, grade 1 was observed in 12 patients (1.6%) and grade 2 was absent. No 3 or 4 hemorrhage grade was encountered in both groups. There was not significant difference in grade 1 hemorrhage between both groups (P=0.21).
Oral anticoagulants were not associated with a significant increase in potentially sight-threatening local anesthetic complications.
检查在需要球周麻醉的眼科手术中继续使用口服抗凝剂的安全性。
一项前瞻性病例对照研究，A组纳入750例服用口服抗凝剂的患者，B组纳入750例从未接受过口服抗凝剂治疗的患者。出血情况分级如下：1）眼睑点状瘀斑和/或结膜下出血；2）眼睑瘀斑累及眼睑表面积的一半；3）眼周全周眼睑瘀斑，眼压无升高；4）球后出血伴眼压升高。
A组中，13例患者出现1级出血（1.74%），2例患者出现2级出血（0.26%）。B组中，12例患者出现1级出血（1.6%），未出现2级出血。两组均未出现3级或4级出血。两组1级出血情况无显著差异（P = 0.21）。
口服抗凝剂与潜在威胁视力的局部麻醉并发症显著增加无关。
